… Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal growth factor
… We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring …

… treatment. EGFR-activating mutations (exon 19 deletions or exon 21 L858R point mutations)
… a significant increase in clinical benefit of erlotinib treatment. The use of erlotinib in patients …

… [5] In this review, we will discuss the clinical outcome of erlotinib in … [17,18] The role of
erlotinib in EGFR mutated patients will be … Here we will review the clinical outcome of erlotinib in …

… enrolled in erlotinib treatment after a first round of unsuccessful chemotherapy to improve …
before the onset of erlotinib treatment and the clinical outcome parameters for patients without …

… paclitaxel/carboplatin with erlotinib or erlotinib alone. The … treatment outcome suggested
that the concurrent addition of chemotherapy to erlotinib did not improve treatment outcomes …

… Erlotinib treatment as a single agent has been evaluated in advanced NSCLC patients after
failure of one or two standard chemotherapy regimens in a large (731 patients), multicenter …

… , survival after treatment with erlotinib was not … clinical outcome. Non–small-cell lung cancer
frequently expresses EGFR, 6-14 and for this reason, it is of considerable interest for clinical …

… , the clinical outcomes among the three EGFR tyrosine kinase inhibitors (TKIs) are still
controversial. We aimed to evaluate clinical outcomes … received treatment with gefitinib, erlotinib or …

… There was no significant difference in survival associated with erlotinib treatment, as …
Correlation between EGFR gene and protein expression data with clinical outcome from BR.…

… In a phase I study, 73% of patients treated with erlotinib experienced skin toxicity and these
had drug plasma concentrations at 24 h significantly higher than those with no skin toxicity […